BCMA-targeted PET imaging probe for diagnosing multiple myeloma.
Official title: Clinical PET Imaging Evaluation of 68Ga-BC1 Probe in Multiple Myeloma
Run by Peking University First Hospital · NCT06717113 · Data updated 2026-11-12
We will test a new 68Ga-labeled BCMA-targeted PET probe (68Ga-MM-BC1) to see if it detects multiple myeloma more accurately in people suspected of or diagnosed with the disease.
Quick facts
| Phase | Early Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | Peking University First Hospital Academic / other |
| Locations | 2 sites (Beijing, Beijing Municipality and 1 other locations) |
| Status | Recruiting |
| Started | April 15, 2025 |
| Main results expected | December 31, 2025 |
| Study ends | December 2028 |
| Registry record updated | June 6, 2025 |
| Trial ID | NCT06717113 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults suspected of multiple myeloma who have had or are scheduled for bone marrow aspiration or tissue biopsy within three months, or adults with symptomatic, diagnosed multiple myeloma who can provide informed consent and tolerate PET imaging.
✕Probably not a fit
Pregnant individuals, people unable to understand or cooperate with the imaging process, and patients whose tumors express very low BCMA are unlikely to benefit from this procedure.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This early-phase study uses a small peptide or nanobody that binds BCMA, radiolabeled with gallium-68 (68Ga-MM-BC1), to perform immuno-PET imaging in patients with suspected or confirmed multiple myeloma. The approach aims to overcome limitations of full-length antibody probes by producing faster tumor uptake and higher target-to-background ratios. Participants will undergo 68Ga-MM-BC1 imaging, with standard 18F-FDG PET as a comparator when applicable, and imaging findings will be correlated with recent bone marrow or tissue biopsy results. The trial focuses on diagnostic performance and feasibility in a clinical setting.
Why it matters
Potential benefit: If successful, the probe could improve detection of myeloma lesions, reduce false-negative biopsies, and help guide more precise treatment decisions.
How similar studies have gone: Preclinical and some early human immuno-PET work targeting BCMA and using small probes like nanobodies has shown promise, but 68Ga-MM-BC1 is a novel early-phase clinical test.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Suspected multiple myeloma patients scheduled for bone marrow aspiration or tissue biopsy within the past 3 months; able to fully understand and voluntarily participate in the study, with signed informed consent; able to cooperate with the examination. * Diagnosed symptomatic multiple myeloma patients; able to fully understand and voluntarily participate in the study, with signed informed consent; able to cooperate with the examination. Exclusion Criteria: * Pregnant women; individuals unable to understand the examination process or who are unable to cooperate.
Where it's running
-
Department of Nuclear Medicine, Peking University First Hospital
Beijing, Beijing Municipality, China Recruiting -
Peking University First Hospital
Beijing, Beijing Municipality, China Enrolling by invitation
Study contacts
- Principal investigator: Tianyao Wang, Ph.D. — Peking University First Hospital
- Study coordinator: Tianyao Wang, PhD
- Email: tianyao.wang@pkufh.com
- Phone: 9298551137
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
BCMA PET/CT to visualize myeloma and related plasma cell disorders
A multicenter study tests whether 68Ga-BCMA PET/CT can noninvasively detect active multiple myeloma and related diseases in patients.
-
Epidural hydroxyethyl starch to prevent post-dural puncture headache in parturients
This study tests whether filling the epidural space with hydroxyethyl starch can help prevent post-dural puncture headaches in women who had an accidental dural puncture during epidural anesthesia for labor or cesarean delivery.
-
AI-powered sleep staging and sleep apnea screening using multimodal wearable data
This study tests AI models that use wearable and sensor data to help identify sleep stages and screen for obstructive sleep apnea in adults undergoing standard sleep testing.
-
Nectin-4 PET/CT imaging to differentiate renal tumors
This study tests a new PET tracer, 18F-N230A, to see if it helps distinguish renal cell carcinoma from renal pelvic urothelial carcinoma in adults.
-
Rituximab plus Cyclosporine for Primary Membranous Nephropathy
This study tests whether adding Cyclosporine to Rituximab helps people with primary membranous nephropathy achieve remission of heavy protein in the urine faster.
-
See if Modified Zhixiao Tongmai Ning can keep kidneys healthier during radiotherapy for kidney cancer
This randomized phase 2 trial tests whether Modified Zhixiao Tongmai Ning helps prevent radiation-related kidney injury in patients with kidney cancers who are receiving radiotherapy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.